Bioequivalence of Telmisartan Film-coated Tablet Compared With the Conventional Telmisartan Tablet Following Oral Administration in Healthy Male Volunteers

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

Study to investigate the bioequivalence of the 40 mg telmisartan film-coated tablet vs. the conventional 40 mg telmisartan tablet

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Telmisartan

Criteria

Inclusion Criteria:

Healthy males according to the following criteria:

1. Based upon a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate, body temperature), 12-lead ECG, clinical laboratory tests

• No findings deviating from normal and of clinical relevance

• No evidence of a clinically relevant concomitant disease

2. Age ≥20 and ≤35 years

3. Body mass index (BMI) ≥17.6 and ≤26.4 kg/m2

4. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation

Exclusion Criteria:

1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders

2. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders

3. Chronic or relevant acute infections

4. Any clinical relevant findings of the laboratory test deviating from normal

5. Positive result for either hepatitis B surface antigen (HBs antigen), anti hepatitis C virus (HCV) antibodies, syphilitic test or human immunodeficiency virus (HIV) test

6. History of surgery of gastrointestinal tract (except appendectomy)

7. History of relevant orthostatic hypotension (mean standing systolic blood pressure (SBP) varies by ≥20 mmHg from mean supine SBP or mean standing diastolic blood pressure (DBP) varies by ≥10 mmHg from mean supine DBP), fainting spells or blackouts

8. History of hepatic dysfunction (e.g. biliary cirrhosis, cholestasis)

9. History of serious renal dysfunction

10. History of bilateral renal artery stenosis or renal artery stenosis in a solitary kidney

11. History of cerebrovascular disorder

12. History of hyperkalemia

13. Known hypersensitivity to any component of the telmisartan formulation, or to any other angiotensin II receptor blockers (ARBs)

14. Intake of drugs with a long half-life (>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial

15. Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 7 days prior to administration or during the trial

16. Participation in another trial with an investigational drug within 4 months or 6 half-lives of the investigational drug prior to administration

17. Smoker (≥20 cigarettes/day)

18. Alcohol abuse (60 g or more ethanol/day: ex. 3 middle-sized bottles of beer, 3 gous (equivalent to 540 mL) of sake)

19. Drug abuse

20. Blood donation (more than 100 mL within 4 weeks prior to administration or during the trial)

21. Excessive physical activities (within 1 week prior to administration or during the trial)

22. Intake of alcohol within 2 days prior to administration

23. Inability to comply with dietary regimen of study centre

24. Inability to refrain from smoking on trial days